Physician profile
Mandeep Singh
NPI 1669638391
$8,651.04
in general payments reported to CMS, 2019-2025
41 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $844 · 2021: $1,702 · 2022: $387 · 2023: $1,416 · 2024: $1,432 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,551.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,519.79 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,030.58 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $649.81 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $596.71 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $592.49 | 2019-2025 | Entyvio |
| Boston Scientific Corporation | $429.28 | 2019-2025 | Axios, Autotome Rx 49, Resolution 360 Ultra Clip |
| Aimmune Therapeutics, INC. | $341.94 | 2024-2025 | Vowst, Zenpep |
| Nestle Healthcare Nutrition INC. | $335.17 | 2020-2023 | |
| Pfizer INC. | $218.61 | 2019-2025 | |
| Cook Medical LLC | $188.25 | 2019-2025 | Fusion, Evolution, Caesar |
| Phathom Pharmaceuticals, INC. | $162.70 | 2025 | Voquezna |
| Genzyme Corporation | $147.95 | 2022-2023 | |
| Madrigal Pharmaceuticals | $132.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $125.03 | 2021-2024 | Zeposia |
| Shionogi INC | $100.39 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $86.23 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $85.47 | 2020-2024 | Linzess |
| Baxter Healthcare | $79.15 | 2023 | |
| Ardelyx, INC. | $74.57 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $73.61 | 2019-2023 | Ocaliva |
| Sumitomo Pharma America, INC. | $71.59 | 2023-2024 | Gemtesa |
| Vivus LLC | $67.11 | 2023-2025 | Pancreaze |
| Ferring Pharmaceuticals INC. | $66.81 | 2021-2023 | Rebyota |
| Ambu INC. | $52.77 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $52.40 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $46.79 | 2019-2021 | |
| Echosens North America, INC. | $44.08 | 2024-2025 | Fibroscan, Fibroscan |
| Organon LLC | $43.33 | 2025 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $37.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.39 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.18 | 2023 | Cyltezo |
| Capsovision, INC. | $20.60 | 2024 | Capsocam Plus |
| Micro-Tech Endoscopy USA, INC. | $19.80 | 2024 | Eyemax |
| Alfasigma USA, INC. | $19.18 | 2020 | |
| Redhill Biopharma INC. | $18.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2025 | Wainua |
| Novo Nordisk INC | $14.44 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $13.71 | 2023 | Dificid, Zinplava |
| Ethicon US, LLC | $12.30 | 2021 | |
| Covidien LP | $12.10 | 2019 | |
| Shire North American Group INC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.